Intravitreal Faricimab in treatment-naive neovascular age-related macular degeneration: real-world outcome of 12-week extension after the loading dose from a UK centre.

ABSTRACT:

Objectives

To assess the visual outcome of extension to 12-weekly intervals (Q12W) following 4 loading doses of intravitreal Faricimab injections as described in the TENAYA and LUCERENE trials for the management of treatment-naïve neovascular Age-related Macular Degeneration (nAMD).

Methods

A retrospective analysis was carried out on all treatment-naïve nAMD patients who started Faricimab intravitreal injections in the period between 1^st September 2022 and 31^st January 2023. The data collection included best corrected visual acuity (BCVA) at baseline, 12 weeks, 24 weeks and 52 weeks; Central Subfield Thickness (CST) at baseline, 24 weeks and 52 weeks; Number of injections at 52 weeks; treatment intervals at 52 weeks. Descriptive and correlational analys

SUBMITTER: Patwardhan A 

PROVIDER: S-EPMC11885585 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature